July 2026 FDA Peptide Update: What the PCAC Vote Means

FDA Advisory Committee Recommends 6 Peptides for Compounding: The July 2026 PCAC Update

By Kevin Jones, MD, Medical Director, Flow Wellness. Updated August 2026.

Quick summary: On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee, known as the PCAC, reviewed seven peptides and recommended adding six of them to the Section 503A compounding list: BPC-157, TB-500, KPV, MOTS-c, semax, and epitalon. The committee voted against emideltide, also called DSIP. This was an important step, but it is not a change in the law. As of today these peptides still cannot be legally compounded, and they will not be until the FDA completes a formal rulemaking process. Here is what happened, what it means, and what it does not mean for patients who want safe, physician-supervised peptide therapy.

What the PCAC Decided in July 2026

The PCAC is an independent panel of experts that reviews the science on compounded medications and makes recommendations to the FDA. Over a two-day meeting on July 23 and 24, 2026, the committee evaluated seven peptides that patients and clinicians have been asking about for years.

After hearing presentations and debating the evidence, the committee recommended that six of the seven peptides be added to the list of bulk drug substances that licensed pharmacies can use to compound medications under Section 503A of the Federal Food, Drug, and Cosmetic Act. The six recommended peptides were BPC-157, TB-500, KPV, MOTS-c, semax, and epitalon. The committee recommended against emideltide, which is also known as delta sleep-inducing peptide or DSIP.

The votes were close and often split. That matters, because it reflects a real tension at the meeting. FDA reviewers had written before the meeting that there is limited evidence to fully evaluate the safety and effectiveness of these specific compounds, and some scientists restated those concerns in person. The committee still recommended most of the peptides for the list, but this was a debate, not a rubber stamp.

What a Spot on the 503A List Actually Means

If the FDA follows these recommendations, being placed on the 503A list would mean the following:

• Licensed 503A and 503B compounding pharmacies could legally prepare these peptides again
• A prescription from a licensed clinician would still be required
• Pharmacies would still have to meet quality standards for sterility and purity
• The raw ingredients would need to come from regulated suppliers

Being added to the list does not make a peptide an FDA-approved drug. Full FDA approval requires large clinical trials that demonstrate safety and effectiveness for a specific medical use. A spot on the 503A list simply restores legal compounding access under medical supervision. It is a return to a regulated channel, not a stamp of approval for any particular use.

How We Got Here

The current situation has been building for a few years.

Between 2023 and 2024, the FDA moved a group of commonly compounded peptides into a restricted category that effectively stopped pharmacies from preparing them, even for patients who had been using them responsibly under a clinician’s care. The agency cited limited human safety data and questions about immune response.

In early 2026, the conversation shifted. Health and Human Services Secretary Robert F. Kennedy Jr., a public supporter of peptide therapy, argued that patients should have more access. In April 2026, the FDA removed seven of these peptides from the restricted category, which made them eligible for review rather than blocked outright. That review is what led to the July 2026 PCAC meeting.

Why This Matters for Patients

When these peptides were restricted, demand did not disappear. Many people turned to overseas suppliers, vendors selling products labeled “research use only,” and online gray-market platforms.

Those products often lack sterility testing, purity verification, and accurate dosing. Contamination and mislabeling are real risks, not hypothetical ones. Restricting regulated access had the unintended effect of pushing some patients toward less safe alternatives.

If compounding access is restored through proper rulemaking, patients would be able to return to physician-supervised, pharmaceutical-grade channels. That is always the safer path, and it is the entire reason a regulated compounding pathway exists.

What Happens Next

The FDA now reviews the committee’s recommendations and decides whether to begin the rulemaking needed to add these peptides to the 503A list. There is no fixed deadline, and the agency can accept, modify, or decline the recommendations.

A second PCAC meeting is expected before the end of February 2027 to review five additional peptides, including Melanotan II. So this is a multi-step process that will continue to unfold into 2027.

We will keep watching the Federal Register and FDA announcements, and we will update this page as the process moves forward.

What This Means at Flow Wellness

Our approach to peptide therapy does not change with a headline. At Flow Wellness we have always practiced peptide medicine through a clinical lens:

• A comprehensive consultation before anything is prescribed
• Baseline labs when appropriate
• Individualized treatment plans built around your goals and health data
• Ongoing monitoring and adjustment
• Pharmaceutical-grade sourcing through licensed pharmacies

We do not support gray-market purchasing or unsupervised peptide use, and that will remain true regardless of how the regulations settle. If these peptides return to legal compounding status, licensed pharmacies may resume preparing them under prescription, and we will incorporate them responsibly. If they do not, we will continue to work within the guidelines as they stand. Safety and compliance come first, every time.

What You Should Do Now

There is no need to rush or stockpile anything. Until the FDA formally updates its guidance, the smart moves are simple:

• Avoid buying peptides from unregulated or “research only” sources
• Keep working with a licensed medical provider
• Wait for confirmed regulatory publication before assuming access has changed

When the rules do change, we will communicate clearly with our patients and talk through whether any newly available peptide fits your goals.

If you want to understand where peptide therapy fits into your own health picture, the best next step is a conversation with our clinical team in Bend, Oregon, in Seattle, Washington, or by telehealth across Oregon, Washington, and California.